Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After A 108% One Year Rally?

Simply Wall St.

Feb 25

This article explores whether Mirum Pharmaceuticals, at a share price of US$105.89, may still offer value or whether the current price already reflects a high level of optimism, by examining what the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614741805"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614741805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614741805?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-25 01:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614741805","market":"hk","top_or_hot":-1,"title":"Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After A 108% One Year Rally?","media":"Simply Wall St.","content":"<div>\n<p>This article explores whether Mirum Pharmaceuticals, at a share price of US$105.89, may still offer value or whether the current price already reflects a high level of optimism, by examining what the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/is-it-too-late-to-consider-mirum-pharmaceuticals-mirm-after-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After A 108% One Year Rally?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Mirum Pharmaceuticals (MIRM) After A 108% One Year Rally?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-25 01:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/is-it-too-late-to-consider-mirum-pharmaceuticals-mirm-after-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This article explores whether Mirum Pharmaceuticals, at a share price of US$105.89, may still offer value or whether the current price already reflects a high level of optimism, by examining what the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/is-it-too-late-to-consider-mirum-pharmaceuticals-mirm-after-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/is-it-too-late-to-consider-mirum-pharmaceuticals-mirm-after-1","article_id":"2614741805","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/is-it-too-late-to-consider-mirum-pharmaceuticals-mirm-after-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614741805","pubTimestamp":1771953800,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"This article explores whether Mirum Pharmaceuticals, at a share price of US$105.89, may still offer value or whether the current price already reflects a high level of optimism, by examining what the market valuation might be indicating.\nThe stock has delivered returns of 2.7% over the last 7 days, 12.3% over 30 days, 35.6% year to date and 107.8% over 1 year, with a very large 3 year return and a 4.7x gain over 5 years that may have influenced how investors view its risk and reward...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MIRM":"Mirum Pharmaceuticals, Inc.","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"在一年上涨108%之后，考虑Mirum Pharmaceuticals(MIRM)是否为时已晚？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":1.5,"DCF":1},"content_text":"This article explores whether Mirum Pharmaceuticals, at a share price of US$105.89, may still offer value or whether the current price already reflects a high level of optimism, by examining what the market valuation might be indicating. The stock has delivered returns of 2.7% over the last 7 days, 12.3% over 30 days, 35.6% year to date and 107.8% over 1 year, with a very large 3 year return and a 4.7x gain over 5 years that may have influenced how investors view its risk and reward profile. Recent attention on Mirum Pharmaceuticals has focused on its position in the pharmaceuticals and biotech space and how its pipeline and approvals align with broader healthcare themes. This context helps explain the recent share price activity and is relevant for both long term holders and new investors when considering whether the current price still matches the company’s fundamentals. On our 6 point valuation checklist, Mirum Pharmaceuticals currently has a value score of 3 out of 6, placing it in the middle of the range between potentially cheap and potentially expensive. The next step is to review traditional valuation approaches and then consider a more comprehensive framework for thinking about what the market may not be fully reflecting.  Mirum Pharmaceuticals delivered 107.8% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: Mirum Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and then discounting those back to a present value. For Mirum Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is US$23.39 million. Analyst projections, combined with extrapolations by Simply Wall St, point to free cash flow reaching US$590.60 million in 2030, with intermediate years such as 2026 and 2027 at US$72.56 million and US$135.41 million respectively. These future figures are discounted back to today in US$, and the sum of those discounted cash flows results in an estimated intrinsic value of US$351.20 per share. Compared with the current share price of US$105.89, this DCF output suggests an implied discount of 69.8%. On this model alone, the stock screens as materially undervalued. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Mirum Pharmaceuticals is undervalued by 69.8%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks. MIRM Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Mirum Pharmaceuticals. Approach 2: Mirum Pharmaceuticals Price vs Sales For a company like Mirum Pharmaceuticals, where earnings metrics are less informative, the P/S ratio is a useful way to compare what investors are paying for each dollar of revenue. Growth expectations and risk usually explain why one stock might trade at a higher or lower P/S multiple than another. Faster and more predictable growth, with lower perceived risk, can justify a higher “normal” or “fair” multiple, while higher uncertainty tends to pull that multiple down. Mirum Pharmaceuticals currently trades on a P/S of 13.44x, compared with the Biotechs industry average of 11.67x and a peer group average of 18.56x. Simply Wall St’s Fair Ratio for Mirum, which is 9.05x, estimates the P/S level that might be appropriate after considering factors such as its earnings growth profile, industry, profit margins, market cap and specific risks. This Fair Ratio approach can be more informative than a simple peer or industry comparison because it adjusts for differences in growth prospects, risk and business quality, rather than assuming all companies in a sector deserve similar multiples. Set against the Fair Ratio of 9.05x, the current 13.44x P/S suggests Mirum Pharmaceuticals may be trading above that model-based estimate. Result: OVERVALUED NasdaqGM:MIRM P/S Ratio as at Feb 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies. Upgrade Your Decision Making: Choose your Mirum Pharmaceuticals Narrative Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, a simple tool on Simply Wall St's Community page that lets you connect your view of Mirum Pharmaceuticals to specific forecasts for revenue, earnings and margins. You can then compare the Fair Value that results from that story with the current price to help you consider whether to buy, hold or sell, knowing that these Narratives automatically refresh as new news or earnings arrive. Different investors can reasonably land in very different places, for example a more cautious view closer to a US$56.92 fair value or a more optimistic view around US$140, depending on how they interpret the same information.* For Mirum Pharmaceuticals however we will make it really easy for you with previews of two leading Mirum Pharmaceuticals Narratives: These sit on opposite sides of the debate, so you can quickly see what needs to be true for a more optimistic or more cautious view to make sense at today’s price. 🐂 Mirum Pharmaceuticals Bull Case Fair value in this bullish narrative: US$140.00 per share Implied discount to that fair value at US$105.89: about 24.4% Assumed annual revenue growth: 23.53%  Analysts backing this view see Mirum broadening its rare disease reach as diagnosis improves and more patients start treatment, with international markets adding meaningful extra revenue. They assume margins improve as revenue scales, with earnings moving from a loss today to solid profitability by 2028 while the market is willing to pay a higher P/E multiple than the wider US Biotechs industry. This narrative leans on continued strength from the existing portfolio, a busy 2026 with guidance that holds up, and ongoing access to capital to fund pipeline and potential acquisitions without derailing profitability.  🐻 Mirum Pharmaceuticals Bear Case Fair value in this cautious narrative: US$95.00 per share Implied premium to that fair value at US$105.89: about 11.5% Assumed annual revenue growth: 23.90%  Analysts here are more concerned that high expectations leave little room for error, given reliance on key assets like Livmarli, upcoming trial readouts and tighter reimbursement conditions for rare disease drugs. They still factor in revenue and margin improvement, but expect earnings to be lower relative to today’s share price, which would require a very high future P/E multiple to justify current levels. This view focuses on risks around pricing pressure, competition, regulatory outcomes and the possibility that 2026 guidance and clinical milestones do not fully support the valuation already embedded in the stock.  If you want to see how these bullish and cautious views link back to detailed assumptions on revenue, margins, and trial outcomes, and how other investors are framing the story, Curious how numbers become stories that shape markets? Explore Community Narratives. Do you think there's more to the story for Mirum Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGM:MIRM 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}